Showing results (181-190 of 367) with videos related to

Sort By:
Pageof 37
American Journal of Hypertension|May 6, 2020
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME TrialJoão Pedro Ferreira, David Fitchett, Anne Pernille Ofstad, et al.
The American Journal of Cardiology|September 29, 2005
In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk scoreAndrew T Yan, Raymond T Yan, Mary Tan, et al.
The New England Journal of Medicine|June 15, 2016
Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesChristoph Wanner, Silvio E Inzucchi, John M Lachin, et al.
American Heart Journal|January 6, 2005
Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndromeAndrew T Yan, Philip Jong, Raymond T Yan, et al.
Tissue Engineering. Part A|February 10, 2015
Application of Modular Therapy for Renoprotection in Experimental Chronic Kidney DiseaseDavid M Kepecs, Yanling Zhang, Kerri Thai, et al.
Clinical Cardiology|September 1, 2021
Atrial structure and function in middle-aged, physically-active males and females: A cardiac magnetic resonance studyMeghan Glibbery, Laura Banks, Mustafa A Altaha, et al.
International Journal of Cardiology|February 21, 2024
Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysisSean Cai, Hourmazd Haghbayan, Kelvin K W Chan, et al.
ESC Heart Failure|June 16, 2021
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trialSubodh Verma, Lawrence A Leiter, Bernard Zinman, et al.
The American Journal of Pathology|April 26, 2011
Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanismAndrew Advani, Qingling Huang, Kerri Thai, et al.
Cardiovascular Diabetology|February 10, 2020
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fractionKim A Connelly, Yanling Zhang, Jean-François Desjardins, et al.
Pageof 37